DOI: 10.1055/s-00000094

Zeitschrift für Gastroenterologie


Cremolini C. et al.
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

Lancet Oncol 2015;
16: 1306-1315

Download Bibliographical Data

Search in: